Adocia (XPAR:ADOC) Common Stock : €1.50 Mil (As of Jun. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Adocia Common Stock?

Adocia's quarterly common stock increased from Jun. 2023 (€0.98 Mil) to Dec. 2023 (€1.41 Mil) and increased from Dec. 2023 (€1.41 Mil) to Jun. 2024 (€1.50 Mil).

Adocia's annual common stock increased from Dec. 2021 (€0.73 Mil) to Dec. 2022 (€0.87 Mil) and increased from Dec. 2022 (€0.87 Mil) to Dec. 2023 (€1.41 Mil).

Adocia Common Stock Historical Data

The historical data trend for Adocia's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adocia Common Stock Chart

Adocia Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.70

0.73

0.87

1.41

Adocia Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Common Stock	Get a 7-Day Free Trial															0.81	0.87	0.98	1.41	1.50

Adocia Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Adocia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adocia (XPAR:ADOC) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

0QAI:UK A89:Germany

Address

115 Avenue Lacassagne, Lyon, FRA, 69003

Website

https://www.adocia.com

Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.